MENLO PARK, CA--(Marketwire - October 15, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, announced today that Daniel M. Bradbury has been appointed to the Company’s Board of Directors.
“We are pleased that Dan has joined our Board,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “His long experience with every aspect of the biotech industry, from drug discovery through approval and product launch, will be invaluable as we commercialize Korlym™ for Cushing’s syndrome, continue our Phase 3 trial of mifepristone for the treatment of the psychotic features of psychotic depression and pursue development of our next-generation GR-II antagonists.”
Mr. Bradbury’s career in the biotechnology and pharmaceutical industry spans 30 years. He served as Chief Executive Officer of Amylin Pharmaceuticals, Inc. from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. From June 2006 until August 2012 he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin’s President (2006-2007), Chief Operating Officer (2003-2006) and Executive Vice President (2000-2003). From 1994-2003 he held a variety of sales and marketing positions at the company. Before joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He also serves on the board of directors of Illumina, Inc., Geron Corporation and Castle Biosciences, Inc., the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee.
Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management’s Advisory Council, the RAND Health Board of Advisors and the University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
“This is an exciting time for Corcept,” said Mr. Bradbury. “Its platform of cortisol receptor antagonists, of which I believe Korlym for endogenous Cushing’s syndrome is just the first, could generate treatments for many severe illnesses.” He added, “I look forward to helping bring those medicines to patients.”
